
ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

Secarna Pharmaceuticals partners with SciNeuro Pharmaceuticals
According to the agreement, Secarna Pharmaceuticals GmbH & Co KG (Planegg, Germany) will identify and validate antisense locked nucleic acid...

Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

Collaboration to fight cancer
Cancer Research UK and UCB SA have announced to advance two cancer antibodies of the Brussels-based biopharma company to the clinical testing stage....

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

New partnerships push InDevR for Series B financing
Investments into InDevR, Inc. came from New York-based Adjuvant Capital ($4m) and French bioMèrieux SA ($5m), which will enable the commercial...